Bradley attorneys represented CirculoGene Theranostics, LLC, a provider of a liquid biopsy for cancer, in connection with its formation, Series A preferred equity financing, and commercial launch. This high-profile startup raised its Series A round to fund further research and development relating to its proprietary and market-disruptive method of enhancing cell-free DNA and its processes for analyzing genetic tumor mutations found in the resulting material, as well as to expand sales and build out its CLIA laboratory.
The company’s launch involved multiple complex regulatory and intellectual property issues, as well as determining the optimal type of entity and structuring its Series A investment terms. A successful formation, launch, and financing of a high-growth biotech company requires experienced legal counsel who not only have substantial experience and understanding of the myriad intricacies of the applicable legal laws, rules, and regulations, but also a firm grasp on the strategic goals and business objectives of the start-up to provide specific practical advice to the company founders.
Bradley served as sole corporate counsel to CirculoGene with respect to its formation and launch, and the company successfully completed its Series A financing in August 2015. The firm dedicated an extensive cross-disciplinary team to the company. Attorneys leveraged their collective years of experience representing hundreds of start-up companies to provide the skills, knowledge, and vision to help the company founders secure a successful launch.